<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121471</url>
  </required_header>
  <id_info>
    <org_study_id>2003H0122</org_study_id>
    <nct_id>NCT01121471</nct_id>
  </id_info>
  <brief_title>Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)</brief_title>
  <acronym>WDS</acronym>
  <official_title>Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cognis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the role of CLA as a complementary therapy to
      improve body composition, glucose tolerance, fasting plasma glucose and insulin, and
      hemoglobinA1c (HbA1c) in subjects with type 2 diabetes mellitus (T2DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design is a double-blind, placebo-controlled, crossover study conducted at a single site.
      The primary variable is a change from baseline to Week 16 in plasma glucose area under the
      curve during a three-hour oral glucose tolerance test. Secondary variables include changes in
      fasting levels of glucose and insulin, glucose tolerance, hemoglobinA1c, hepatic enzymes,
      adipocytokines, blood lipid profile, and body composition. Supporting endpoints include
      dietary intake, physical activity, fatty acids, and vital signs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in plasma glucose AUC</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>significant change in plasma glucose AUC (0-3 h) from baseline to Week 16.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in insulin sensitivity</measure>
    <time_frame>baseline and every 4 weeks until week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in glucose tolerance</measure>
    <time_frame>baseline and every 4 weeks for 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in HbA1c</measure>
    <time_frame>baseline and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood lipid profile</measure>
    <time_frame>baseline and every 4 weeks for 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum adipocytokines</measure>
    <time_frame>baseline and every 4 weeks for 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in hepatic enzymes</measure>
    <time_frame>baseline and every 4 weeks for 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in body composition</measure>
    <time_frame>baseline and every 4 weeks for 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Safflower Oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8.0 g/day safflower oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLA 6.4g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conjugated linoleic acid at a dose of 6.4g/day in a supplement with a total of 8.0g oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Conjugated Linoleic Acid (CLA)</intervention_name>
    <description>6.4 g CLA/day, capsule form, for 16 week arms</description>
    <arm_group_label>CLA 6.4g/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Safflower OIl</intervention_name>
    <description>8.0g/day safflower oil</description>
    <arm_group_label>Safflower Oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of Type 2 diabetes mellitus

          -  obese

          -  postmenopausal

          -  HbA1c &gt;6.49 and &lt;14.1

        Exclusion Criteria:

          -  use of tobacco

          -  substance abuse

          -  impaired cognitive function

          -  renal disease

          -  abnormal liver function

          -  gastrointestinal diseases

          -  use of exogenous insulin

          -  use of hormone replacement therapy currently or within past 6 months

          -  pacemaker/defibrillator
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martha A. Belury, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Norris LE, Collene AL, Asp ML, Hsu JC, Liu LF, Richardson JR, Li D, Bell D, Osei K, Jackson RD, Belury MA. Comparison of dietary conjugated linoleic acid with safflower oil on body composition in obese postmenopausal women with type 2 diabetes mellitus. Am J Clin Nutr. 2009 Sep;90(3):468-76. doi: 10.3945/ajcn.2008.27371. Epub 2009 Jun 17.</citation>
    <PMID>19535429</PMID>
  </results_reference>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>May 10, 2010</last_update_submitted>
  <last_update_submitted_qc>May 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Martha A. Belury</name_title>
    <organization>The Ohio State University</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>conjugated linoleic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

